SC
AKBA icon

Sykon Capital’s Akebia Therapeutics AKBA Stock Holding History

Sykon Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$15.3K – 94
2024
Q2 		$15.3K Hold
15,000
– – 0.01% 90
2024
Q1 		$27.4K Hold
15,000
– – 0.01% 93
2023
Q4 		$18.6K Hold
15,000
– – 0.01% 81
2023
Q3 		$17.1K Hold
15,000
– – 0.01% 56
2023
Q2 		$13.7K Buy
+15,000
New +$14.5K 0.01% 53

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sykon Capital's AKBA Position: Q3 2024 in Review

Sykon Capital sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 15,000 shares — an estimated $15.3K sold.

Sykon Capital first reported a position in AKBA in Q2 2023 and held it in 5 quarters. The position peaked at $27.4K in Q1 2024. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Sykon Capital reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sykon Capital sold 15,000 Akebia Therapeutics shares in Q3 2024, an estimated $15.3K.
  • Sykon Capital first reported a position in Akebia Therapeutics in Q2 2023 and held it in 5 quarters.
  • Sykon Capital's Akebia Therapeutics position peaked at $27.4K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Sykon Capital's 13F filing for Q3 2024, filed 12 Nov 2024.